Stock BLCO BAUSCH + LOMB CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
14.79 USD +0.20% Intraday chart for Bausch + Lomb Corporation +1.02% -13.31%
Apr. 25 Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement MT
Apr. 25 Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 5,429 5,986 5,197 - -
Enterprise Value (EV) 1 7,511 10,217 9,074 8,612 8,938
P/E ratio 776 x -23.1 x -52.8 x 126 x 38.9 x
Yield - - - - -
Capitalization / Revenue 1.44 x 1.44 x 1.12 x 1.06 x 1 x
EV / Revenue 1.99 x 2.46 x 1.95 x 1.75 x 1.72 x
EV / EBITDA 10.4 x 13.8 x 10.4 x 8.88 x 8.35 x
EV / FCF 44.2 x -51.6 x 33.6 x 23.2 x 17.9 x
FCF Yield 2.26% -1.94% 2.97% 4.32% 5.6%
Price to Book 0.77 x 0.87 x 0.74 x 0.7 x -
Nbr of stocks (in thousands) 350,001 350,881 351,402 - -
Reference price 2 15.51 17.06 14.79 14.79 14.79
Announcement Date 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 3,765 3,768 4,146 4,659 4,911 5,195
EBITDA 1 - 720 738 868.9 970.1 1,070
EBIT 1 - 585 596 646.8 727.9 818
Operating Margin - 15.53% 14.38% 13.88% 14.82% 15.75%
Earnings before Tax (EBT) 1 - 73 -166 -96.33 76 169
Net income 1 182 6 -260 -142.7 56.5 127
Net margin 4.83% 0.16% -6.27% -3.06% 1.15% 2.44%
EPS 2 - 0.0200 -0.7400 -0.2800 0.1175 0.3800
Free Cash Flow 1 - 170 -198 269.8 371.7 500.5
FCF margin - 4.51% -4.78% 5.79% 7.57% 9.63%
FCF Conversion (EBITDA) - 23.61% - 31.05% 38.32% 46.76%
FCF Conversion (Net income) - 2,833.33% - - 657.88% 394.09%
Dividend per Share 2 - - - - - -
Announcement Date 3/31/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 889 941 942 996 931 1,035 1,007 1,173 1,068 1,175 1,162 1,255 1,111
EBITDA 1 170 182 187 181 141 179 187 231 176.7 213.3 219.2 257.7 169
EBIT 1 140 148 153 144 107 104 152 195 117.5 157.3 163.5 204.2 117
Operating Margin 15.75% 15.73% 16.24% 14.46% 11.49% 10.05% 15.09% 16.62% 11% 13.39% 14.07% 16.28% 10.53%
Earnings before Tax (EBT) 1 29 27 19 -2 -55 -19 -35 -57 -45 -29 -20.67 -1.667 -
Net income 1 20 5 -18 -1 -90 -32 -84 -54 -55.67 -41.67 -32.33 -13.67 -
Net margin 2.25% 0.53% -1.91% -0.1% -9.67% -3.09% -8.34% -4.6% -5.21% -3.55% -2.78% -1.09% -
EPS 2 0.0600 0.0100 -0.0500 - -0.2600 -0.0900 -0.2400 -0.1500 -0.1540 -0.0960 -0.0720 0.002000 -
Dividend per Share 2 - - - - - - - - - - - - -
Announcement Date 6/8/22 8/4/22 11/2/22 2/22/23 5/3/23 8/2/23 11/1/23 2/21/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - 2,082 4,231 3,877 3,415 3,741
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - 2.892 x 5.733 x 4.461 x 3.52 x 3.495 x
Free Cash Flow 1 - 170 -198 270 372 501
ROE (net income / shareholders' equity) - 4.58% 3.72% 3.17% 4.85% 7.73%
ROA (Net income/ Total Assets) - 3.41% 2.1% 1.71% 2.46% 3.05%
Assets 1 - 175.7 -12,388 -8,349 2,294 4,169
Book Value Per Share 2 - 20.10 19.50 20.10 21.10 -
Cash Flow per Share 2 - 0.9900 -0.0500 0.9600 1.440 1.750
Capex 1 - 175 181 252 234 253
Capex / Sales - 4.64% 4.37% 5.41% 4.75% 4.86%
Announcement Date 3/31/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bausch + Lomb Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
14.79 USD
Average target price
19.79 USD
Spread / Average Target
+33.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
BAUSCH + LOMB CORPORATION Stock Bausch + Lomb Corporation
-13.31% 5.2B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. BLCO Stock
  4. Financials Bausch + Lomb Corporation